Loading
A phase 1/2 trial of Doxorubicin in basal cell carcinoma, run by SkinJect, Inc., active and no longer recruiting.
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) is a phase 1/2 interventional study registered as NCT04928222 by SkinJect, Inc., with 25 participants enrolled, started 2021-09-24 and due to reach its primary completion in 2023-12-30. Interventions recorded: Doxorubicin-containing MNA and Placebo-containing MNA.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.